

Robert C. Green, MD, MPH
Professor of Neurology, Genetics and Epidemiology
Co-Director, Alzheimer's Disease Clinical and Research Program
Boston University Schools of Medicine and Public Health
www.bu.edu/alzresearch

Dr. Green graduated from Amherst College and the University of Virginia School of Medicine before completing a residency in neurology at Harvard Medical School's Longwood Neurology Program. Following this, he completed research fellowships in Behavioral Neurology and Neurophysiology at the Beth Israel Hospital and Children's Hospital in Boston, winning both the William B. Lennox Research Fellowship and the Wilder Penfield Research Fellowship. Dr. Green obtained additional training in Epidemiology, receiving a Masters in Public Health from the Rollins School of Public Health at Emory University.

In 1999, Dr. Green joined the faculty of Boston University School of Medicine where he founded and currently co-directs Boston University's Alzheimer's Disease Clinical and Research Program, and is the Clinical Director of the NIA-funded Alzheimer's Disease Center. Dr. Green is the author of over 130 publications, serves on a number of advisory, editorial and grant review boards, and is past President of the Society for Behavioral and Cognitive Neurology. He has been continuously funded by NIH since 1990 and was voted one of America's "Best Doctors" by his peers.

Dr. Green's research interests are in early and preclinical detection, treatment and prevention of Alzheimer's disease. He is Principal Investigator and Director of the REVEAL Study (Risk Evaluation and Education for Alzheimer's disease) a multi-center project funded by the National Human Genome Research Institute and the National Institute on Aging to develop genetic risk assessment strategies for individuals at risk for Alzheimer's disease.

Dr. Green is also co-Principal Investigator on Boston University's NIH-funded MIRAGE Study (Multi-Institutional Research in Alzheimer's Genetic Epidemiology), co-investigator on the NIH-funded Framingham Dementia Study and NIH-funded Georgia Centenarian Study, and is the Boston site director of the NIH-funded ADAPT Study (Alzheimer's Disease Anti-Inflammatory Prevention Trial), one of the first large-scale intervention trials to prevent the development of Alzheimer's disease in at-risk family members. He is national co-lead investigator on the industry-sponsored phase III trial of tarenflurbil, a compound being evaluated for disease modification in patients with mild Alzheimer's disease. He is a consultant on the following NIH-funded studies: the Cache County Memory and Aging Study, the Epidemiology of Alzheimer's disease in Twins and the Wisconsin Registry for Alzheimer's Prevention Study.